GlassScriptPhysician profile
Megan E Milne
NPI 1720519622
$2,423.63
in general payments reported to CMS, 2019-2025
43 companies · $602 in 2025
The $602 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $380 · 2023: $523 · 2024: $919 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028 · Education: $15.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.92 |
| Education | $15.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $550.50 | 2023-2025 | |
| Amgen INC. | $268.71 | 2022-2025 | Evenity, Enbrel, Prolia |
| Lilly USA, LLC | $219.69 | 2023-2024 | Mounjaro, Zepbound, Taltz |
| Horizon Therapeutics Plc | $171.38 | 2022-2023 | Krystexxa |
| Radius Health, INC. | $105.78 | 2023-2025 | Tymlos |
| Fresenius Kabi USA, LLC | $69.14 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $68.73 | 2024-2025 | Orencia |
| Pfizer INC. | $63.66 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $58.46 | 2022-2025 | Saphnelo |
| Lundbeck LLC | $55.49 | 2024 | Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.45 | 2023-2024 | Ofev |
| Novo Nordisk INC | $55.14 | 2024-2025 | Ozempic, Rybelsus |
| Organon LLC | $44.48 | 2023-2025 | Renflexis |
| Ucb, INC. | $44.27 | 2022-2023 | Cimzia |
| Neurocrine Biosciences, INC. | $39.97 | 2023-2025 | Ingrezza, Ongentys |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Milne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.